Thrombotic Changes in Haemostasis Following Intravenous Streptokinase Treatment for Acute Myocardial Infarction

Thromb Haemost 1990; 63(01): 146-147
DOI: 10.1055/s-0038-1645707

Letter to the Editor

Schattauer GmbH Stuttgart

M Udvardy

2nd Department of Medicine, University Medical School, Debrecen, Hungary

,

J Hársfalvi

2nd Department of Medicine, University Medical School, Debrecen, Hungary

,

Z Boda

2nd Department of Medicine, University Medical School, Debrecen, Hungary

,

K Rak

2nd Department of Medicine, University Medical School, Debrecen, Hungary

References
1 Simoons ML. Thrombolytic therapy in acute myocardial infarction. Ann Rev Med 1989; 40: 181-187
2 Bates ER, Topol EJ. Thrombolytic therapy for acute myocardial infarction. Chest 1989; (Suppl. 95) 257-263
3 Jusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I Treatment following myocardial infarction. J Am Med Assoc 1988; 260: 2089-2093
4 Naylor CD, Armstrong PW. Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Can Med Assoc J 1989; 140: 1289-1299
5 Hogg KJ. ECG evidence of myocardial salvage after thrombolysis in acute myocardial infarction. Br Heart J 1989; 61: 489-493
6 Rapaport SI. A plasma protein C activity assay suitable for clinical laboratory. Am J Clin Pathol 1989; 87: 491-497
7 Zimmerman TS. Determination of the von Willebrand’s disease antigen in plasma by quantitative immunoelectrophoresis. J Lab Clin Med 1975; 86: 152-159
8 Fitzgerald DJ, Wright F, FitzGerald GA. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane-A₂ modulate the response to tissue type plasminogen activator in vivo. Circulation Res 1989; 65: 83-94